IS1855B - (-) cis-6(S)-fenýl-5(R)-[4-(2-pýrrólidín-1-ýl-etoxý)fenýl]-5,6,7,8-tetrahýdrónaftalen-2-ól-D-tartrat, notkun, lyfjablanda og framleiðsla hennar - Google Patents

(-) cis-6(S)-fenýl-5(R)-[4-(2-pýrrólidín-1-ýl-etoxý)fenýl]-5,6,7,8-tetrahýdrónaftalen-2-ól-D-tartrat, notkun, lyfjablanda og framleiðsla hennar

Info

Publication number: IS1855B
Authority: IS; Iceland
Prior art keywords: phenyl; tetrahydronaphthalen; pyrrolidin; tartrate; cis
Prior art date: 1995-11-02

Application number

IS4718A

Other languages

English (en)

Other versions

IS4718A (is

Inventor

K. Chiu Charles

Meltz Morgan

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1998-04-16

Publication date

2003-02-21

1998-04-16 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1998-04-16 Publication of IS4718A publication Critical patent/IS4718A/is

2003-02-21 Publication of IS1855B publication Critical patent/IS1855B/is

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS4718A 1995-11-02 1998-04-16 (-) cis-6(S)-fenýl-5(R)-[4-(2-pýrrólidín-1-ýl-etoxý)fenýl]-5,6,7,8-tetrahýdrónaftalen-2-ól-D-tartrat, notkun, lyfjablanda og framleiðsla hennar IS1855B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US612595P	1995-11-02	1995-11-02
PCT/IB1996/001049 WO1997016434A1 (en)	1995-11-02	1996-10-04	(-) cis-6(s)-phenyl-5(r)[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate

Publications (2)

Publication Number	Publication Date
IS4718A IS4718A (is)	1998-04-16
IS1855B true IS1855B (is)	2003-02-21

Family

ID=21719433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4718A IS1855B (is)	1995-11-02	1998-04-16	(-) cis-6(S)-fenýl-5(R)-[4-(2-pýrrólidín-1-ýl-etoxý)fenýl]-5,6,7,8-tetrahýdrónaftalen-2-ól-D-tartrat, notkun, lyfjablanda og framleiðsla hennar

Country Status (43)

Country	Link
US (1)	US5948809A (is)
EP (1)	EP0876359B1 (is)
JP (1)	JP3088020B2 (is)
KR (1)	KR19990067280A (is)
CN (1)	CN1067065C (is)
AP (1)	AP713A (is)
AR (1)	AR004078A1 (is)
AT (1)	ATE248827T1 (is)
AU (1)	AU708841B2 (is)
BG (1)	BG63943B1 (is)
BR (1)	BR9611436A (is)
CA (1)	CA2236673C (is)
CO (1)	CO4770967A1 (is)
CZ (1)	CZ287341B6 (is)
DE (1)	DE69629837T2 (is)
DK (1)	DK0876359T3 (is)
DZ (1)	DZ2114A1 (is)
EG (1)	EG21095A (is)
ES (1)	ES2203713T3 (is)
GT (1)	GT199600085A (is)
HR (1)	HRP960503B1 (is)
HU (1)	HU227521B1 (is)
IL (1)	IL124027A (is)
IS (1)	IS1855B (is)
MA (1)	MA23998A1 (is)
NO (1)	NO310358B1 (is)
NZ (1)	NZ318498A (is)
OA (1)	OA11009A (is)
PE (1)	PE17698A1 (is)
PL (1)	PL188633B1 (is)
PT (1)	PT876359E (is)
RO (1)	RO119829B1 (is)
RU (1)	RU2162465C2 (is)
SI (1)	SI0876359T1 (is)
SK (1)	SK282172B6 (is)
TN (1)	TNSN96134A1 (is)
TR (1)	TR199800783T2 (is)
TW (2)	TW581766B (is)
UA (1)	UA51676C2 (is)
UY (1)	UY24362A1 (is)
WO (1)	WO1997016434A1 (is)
YU (1)	YU49123B (is)
ZA (1)	ZA969212B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) *	1997-02-14	1997-04-02	Smith & Nephew	Compositions
ATE265853T1 (de)	1998-06-16	2004-05-15	Pfizer Prod Inc	Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2
PA8475901A1 (es) *	1998-06-16	2000-05-24	Pfizer Prod Inc	Terapia de combinacion para la fragilidad musculoesqueletica
HUP0102395A2 (hu) *	1998-06-16	2001-11-28	Pfizer Products Inc.	Izom- és csontrendszeri gyengeség kezelésére alkalmas szelektív ösztrogén receptor modulátorok és növekedési hormon szekretagógok (GHS) kombinációját tartalmazó gyógyszerkészítmények
YU26700A (sh) *	1999-05-24	2002-06-19	Pfizer Products Inc.	Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271696A1 (es) *	2000-01-12	2003-04-30	Pfizer Prod Inc	Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271697A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es)	2000-01-26	2003-02-28	Pfizer Prod Inc	Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
HK1052511B (zh) *	2000-04-07	2005-09-30	辉瑞产品公司	雌激素激动剂/拮抗剂代谢物
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
ES2274854T3 (es)	2000-05-08	2007-06-01	Pfizer Products Inc.	Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145838A (en) *	2000-10-16	2008-11-03	Pfizer Prod Inc	Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
TWI303990B (en)	2000-10-17	2008-12-11	Pfizer Prod Inc	New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en)	2001-01-26	2005-05-12	Pfizer Products Inc.	Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function
UA75135C2 (en) *	2001-05-01	2006-03-15	Pfizer Prod Inc	Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
SK622004A3 (en)	2001-07-31	2004-08-03	Pfizer Prod Inc	Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
RU2317104C2 (ru) *	2001-09-24	2008-02-20	Импиэриэл Инноувейшнс Лимитид	Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
RU2278861C2 (ru) *	2002-03-28	2006-06-27	Пфайзер Продактс Инк.	Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией
PA8576201A1 (es)	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en)	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en)	2004-05-06	2008-10-28	Smp Logic Systems Llc	Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
BRPI0512342A (pt) *	2004-06-21	2008-03-04	Pharmacia & Upjohn Co Llc	métodos para aumento ósseo
EP1763521A1 (en) *	2004-06-30	2007-03-21	Eli Lilly and Company	1- (indole-6-carbonyl-d-phenylglycinyl)-4- (l-methylpiperidin-4- yl) piperazine d-tartrate
ATE482940T1 (de)	2005-06-22	2010-10-15	Pfizer Prod Inc	Stereoselektives hydrierverfahren zur herstellung von cis-6-phenyl-5-ä4-(2-pyrrolidin-1-yl-ethoxy)- phenylü-2-methoxy-5,6,7,8-tetrahydronaphthalin- hydrochlorid
CZ2007373A3 (cs) *	2007-05-29	2008-12-10	Zentiva, A. S	Zpusob prípravy lasofoxifenu
EP2424839A4 (en)	2009-04-29	2012-10-17	Glenmark Generics Ltd	PROCESS FOR THE PREPARATION OF LASOFOXIFEN TARTRATE
KR101149529B1 (ko)	2009-09-11	2012-05-25	한국화학연구원	인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) *	2013-02-05	2015-11-11	南京华威医药科技开发有限公司	酒石酸拉索昔芬中间体的制备方法
PL3525774T3 (pl)	2016-10-11	2022-04-25	Duke University	Leczenie lazofoksyfenem raka piersi er+
WO2019199891A1 (en)	2018-04-10	2019-10-17	Duke University	Lasofoxifene treatment of breast cancer
KR20220115062A (ko)	2021-02-09	2022-08-17	(주)오스티오뉴로젠	크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2025043004A1 (en)	2023-08-21	2025-02-27	Duke University	Treatment of solid cancer with lasofoxifene

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274213A (en) *	1961-09-05	1966-09-20	Upjohn Co	Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) *	1962-09-10	1966-02-08	Ciba Geigy Corp	Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) *	1964-01-23	1970-07-28	Ciba Geigy Corp	Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

1996
- 1996-04-10 UA UA98042214A patent/UA51676C2/uk unknown
- 1996-09-30 TW TW091125091A patent/TW581766B/zh not_active IP Right Cessation
- 1996-09-30 TW TW085111903A patent/TW518327B/zh not_active IP Right Cessation
- 1996-10-04 CA CA002236673A patent/CA2236673C/en not_active Expired - Lifetime
- 1996-10-04 EP EP96931206A patent/EP0876359B1/en not_active Expired - Lifetime
- 1996-10-04 HU HU9900087A patent/HU227521B1/hu unknown
- 1996-10-04 IL IL12402796A patent/IL124027A/en not_active IP Right Cessation
- 1996-10-04 RU RU98110128/04A patent/RU2162465C2/ru active
- 1996-10-04 KR KR1019980703251A patent/KR19990067280A/ko not_active Ceased
- 1996-10-04 TR TR1998/00783T patent/TR199800783T2/xx unknown
- 1996-10-04 SK SK542-98A patent/SK282172B6/sk not_active IP Right Cessation
- 1996-10-04 CZ CZ19981320A patent/CZ287341B6/cs not_active IP Right Cessation
- 1996-10-04 CN CN96198048A patent/CN1067065C/zh not_active Expired - Lifetime
- 1996-10-04 ES ES96931206T patent/ES2203713T3/es not_active Expired - Lifetime
- 1996-10-04 AT AT96931206T patent/ATE248827T1/de active
- 1996-10-04 PT PT96931206T patent/PT876359E/pt unknown
- 1996-10-04 BR BR9611436A patent/BR9611436A/pt not_active Application Discontinuation
- 1996-10-04 US US09/065,094 patent/US5948809A/en not_active Expired - Lifetime
- 1996-10-04 AU AU69984/96A patent/AU708841B2/en not_active Expired
- 1996-10-04 WO PCT/IB1996/001049 patent/WO1997016434A1/en not_active Ceased
- 1996-10-04 JP JP09517180A patent/JP3088020B2/ja not_active Expired - Lifetime
- 1996-10-04 RO RO98-00926A patent/RO119829B1/ro unknown
- 1996-10-04 NZ NZ318498A patent/NZ318498A/xx not_active IP Right Cessation
- 1996-10-04 DE DE69629837T patent/DE69629837T2/de not_active Expired - Lifetime
- 1996-10-04 DK DK96931206T patent/DK0876359T3/da active
- 1996-10-04 SI SI9630635T patent/SI0876359T1/xx unknown
- 1996-10-04 PL PL96326498A patent/PL188633B1/pl unknown
- 1996-10-11 GT GT199600085A patent/GT199600085A/es unknown
- 1996-10-23 AR ARP960104862A patent/AR004078A1/es active IP Right Grant
- 1996-10-29 HR HR960503A patent/HRP960503B1/xx not_active IP Right Cessation
- 1996-10-30 DZ DZ960158A patent/DZ2114A1/fr active
- 1996-10-30 PE PE1996000753A patent/PE17698A1/es not_active Application Discontinuation
- 1996-10-30 MA MA24381A patent/MA23998A1/fr unknown
- 1996-10-30 TN TNTNSN96134A patent/TNSN96134A1/fr unknown
- 1996-10-30 EG EG95996A patent/EG21095A/xx active
- 1996-10-31 AP APAP/P/1996/000880A patent/AP713A/en active
- 1996-11-01 CO CO96057925A patent/CO4770967A1/es unknown
- 1996-11-01 ZA ZA9609212A patent/ZA969212B/xx unknown
- 1996-11-01 YU YU57896A patent/YU49123B/sh unknown
- 1996-11-04 UY UY24362A patent/UY24362A1/es unknown
1998
- 1998-04-16 IS IS4718A patent/IS1855B/is unknown
- 1998-04-29 OA OA9800046A patent/OA11009A/en unknown
- 1998-04-30 NO NO19981962A patent/NO310358B1/no not_active IP Right Cessation
- 1998-05-21 BG BG102474A patent/BG63943B1/bg unknown

Also Published As

Publication number	Publication date
HRP960503A2 (en)	1998-04-30
BG63943B1 (bg)	2003-07-31
TW581766B (en)	2004-04-01
CO4770967A1 (es)	1999-04-30
HUP9900087A3 (en)	1999-11-29
DZ2114A1 (fr)	2002-07-22
JP3088020B2 (ja)	2000-09-18
SK282172B6 (sk)	2001-11-06
IS4718A (is)	1998-04-16
AU708841B2 (en)	1999-08-12
UY24362A1 (es)	1997-04-24
UA51676C2 (uk)	2002-12-16
US5948809A (en)	1999-09-07
CN1067065C (zh)	2001-06-13
AP713A (en)	1998-12-28
TW518327B (en)	2003-01-21
SI0876359T1 (en)	2003-12-31
CN1201458A (zh)	1998-12-09
PL188633B1 (pl)	2005-03-31
HU227521B1 (en)	2011-07-28
ES2203713T3 (es)	2004-04-16
ATE248827T1 (de)	2003-09-15
CZ132098A3 (cs)	1999-03-17
NO981962D0 (no)	1998-04-30
CZ287341B6 (en)	2000-10-11
JPH11502866A (ja)	1999-03-09
NO310358B1 (no)	2001-06-25
TR199800783T2 (xx)	1998-08-21
PL326498A1 (en)	1998-09-28
BR9611436A (pt)	1999-03-23
AP9600880A0 (en)	1997-01-31
GT199600085A (es)	1998-04-04
AR004078A1 (es)	1998-09-30
HRP960503B1 (en)	2001-12-31
OA11009A (en)	2003-03-03
AU6998496A (en)	1997-05-22
SK54298A3 (en)	1999-07-12
RU2162465C2 (ru)	2001-01-27
PT876359E (pt)	2003-12-31
HUP9900087A2 (hu)	1999-05-28
YU57896A (sh)	1998-12-23
BG102474A (en)	1999-06-30
DE69629837D1 (de)	2003-10-09
WO1997016434A1 (en)	1997-05-09
ZA969212B (en)	1998-05-04
RO119829B1 (ro)	2005-04-29
CA2236673A1 (en)	1997-05-09
DK0876359T3 (da)	2003-11-24
DE69629837T2 (de)	2004-05-06
MA23998A1 (fr)	1997-07-01
PE17698A1 (es)	1998-04-18
MX9803544A (es)	1998-09-30
NZ318498A (en)	1999-06-29
KR19990067280A (ko)	1999-08-16
EP0876359B1 (en)	2003-09-03
EG21095A (en)	2000-10-31
EP0876359A1 (en)	1998-11-11
CA2236673C (en)	2002-03-19
TNSN96134A1 (fr)	1998-12-31
IL124027A (en)	2001-10-31
YU49123B (sh)	2004-03-12
NO981962L (no)	1998-04-30

Publication	Publication Date	Title
IS1855B (is)	2003-02-21	(-) cis-6(S)-fenýl-5(R)-[4-(2-pýrrólidín-1-ýl-etoxý)fenýl]-5,6,7,8-tetrahýdrónaftalen-2-ól-D-tartrat, notkun, lyfjablanda og framleiðsla hennar
NO973479L (no)	1997-09-29	Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
DK0720609T3 (da)	1999-07-26	3-(5-Tetrazolylbenzyl)aminoperidinderivater og antagonister for tachykininer
FI955311A7 (fi)	1996-05-10	Farmaseuttinen koostumuspohja
FI925661L (fi)	1992-12-11	Injicerbar farmaceutisk komposition
ITTO910241A1 (it)	1992-10-03	Cerniera per mobili
NZ236582A (en)	1993-10-26	Azaoxindole derivatives, pharmaceutical compositions and intermediates
ITBZ910002V0 (it)	1991-05-16	Cerniera per mobili
DK0435333T3 (da)	1996-06-24	Cephalosporinderivater, fremgangsmåde til fremstilling deraf og antimikrobielt præparat indeholdende derivaterne
FI910088A7 (fi)	1991-07-10	Oraalinen farmaseuttinen koostumus
BR9507768A (pt)	1997-09-02	Composição farmacêutica
NO303637B1 (no)	1998-08-10	7-disubstituert-metyl-4-okso-3H,5H-pyrrolo-£3,2-d\|pyrimidin, farmas°ytisk preparat, og anvendelse derav
FI973229L (fi)	1997-08-05	Uusi farmaseuttinen koostumus
FI961977A0 (fi)	1996-05-09	N-substituoidut atsabisykloalkaanijohdannaiset, niiden valmistus ja käyttö
UA26064A1 (uk)	1999-04-30	Фармацевтичhа композиція
FI955238A7 (fi)	1996-05-04	Uudet 5-(aryylioksimetyyli)oksatsoliinit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
NO903386D0 (no)	1990-08-01	Fremgangsmaate for fremstilling av 4-(n-substituert amino)-2-butynyl-1-karbamater og -tiokarbamater og derivater derav.
FI971317A7 (fi)	1997-03-27	Uusia heterosyklisiä, substituoituja imidatsolokinoksalinoneja, niiden valmistus ja käyttö
NZ239187A (en)	1993-10-26	Substituted 2-(9-fluorenonyl)-carbapenem derivatives, pharmaceutical compositions, and intermediates
FI956016L (fi)	1996-06-17	1,2-silloitettujen 1,4-dihydropyridiinien käyttö lääkeaineina
IL86752A (en)	1993-01-14	Thiophene derivatives and their preparation and their use as intermediates in the preparation of n-(2,4-dimethylthien-3-yl) -n-(1-methoxyprop-2-yl) - chloroacetamide
BG97014A (bg)	1993-12-24	Производни на 1,5-бензотиазепинон,метод за тяхното получаване и приложението им
ITUD910115A1 (it)	1993-01-23	Cerniera per mobili
IT1272935B (it)	1997-07-01	Composizione farmaceutica contenente n-acetil-cisteina
SE9402924D0 (sv)	1994-09-02	Novel pharmaceutical composition